ABSTRACT
BACKGROUND: Treating obesity may be a pathway to prevent and control hypertension. In the SURMOUNT-1 trial in people with obesity or overweight with weight-related complications, 72-week tirzepatide treatment led to clinically meaningful body weight and blood pressure reduction. Post hoc analyses were conducted to further explore the effects of tirzepatide on the pattern of blood pressure reduction and whether the effects were consistent across various subgroups. METHODS: The mixed effect for repeated measure model was used to compare changes in overall blood pressure, across demographic and clinical subgroups, baseline blood pressure subgroups and hypertension categories between SURMOUNT-1 participants randomised to treatment with tirzepatide and placebo. The association between weight changes and blood pressure and adverse events associated with low blood pressure were also evaluated by mediation analysis. RESULTS: Tirzepatide treatment was associated with a rapid decline in systolic and diastolic blood pressure over the first 24 weeks, followed by blood pressure stabilisation until the end of the observation period, resulting in a significant net reduction by 72 weeks of 6.8 mm Hg systolic and 4.2 mm Hg diastolic blood pressure versus placebo. Participants randomly assigned to any tirzepatide group were more likely than those assigned to placebo to have normal blood pressure at week 72 (58.0% vs 35.2%, respectively). The effects were broadly consistent across baseline blood pressure subgroups, shifting the blood pressure distribution curve to lower blood pressure levels. The mediation analysis indicated that weight loss explained 68% of the systolic and 71% of the diastolic blood pressure reduction. Low blood pressure adverse events were infrequent, but the rate was higher in the tirzepatide group. CONCLUSIONS: In these post hoc analyses, in participants with obesity or overweight, tirzepatide was associated with reduced blood pressure consistently across participant groups primarily via weight loss, with relatively few blood pressure-related adverse events. TRIAL REGISTRATION NUMBER: NCT04184622.
Subject(s)
Diabetes Mellitus, Type 2 , Gastric Inhibitory Polypeptide , Glucagon-Like Peptide-2 Receptor , Hypertension , Adult , Humans , Blood Pressure/physiology , Blood Pressure Monitoring, Ambulatory , Body Mass Index , Hypertension/diagnosis , Hypertension/drug therapy , Hypoglycemic Agents , Glucagon-Like Peptide-1 ReceptorABSTRACT
AIMS: Empagliflozin reduces cardiovascular death (CVD) or heart failure hospitalization (HHF) in patients with heart failure and preserved ejection fraction (HFpEF). Treatment effects and safety in relation to resting heart rate (RHR) have not been studied. METHODS AND RESULTS: The interplay of RHR and empagliflozin effects in EMPEROR-Preserved was evaluated. We grouped patients (n = 5988) according to their baseline RHR (<70 bpm [n = 2650], 70-75 bpm [n = 967], >75 bpm [n = 1736]) and explored the influence of RHR on CVD or HHF (primary outcome) and its components in sinus rhythm or atrial fibrillation/flutter (AF) and adverse events. We studied the efficacy of empagliflozin across the RHR spectrum. Compared to placebo, empagliflozin did not change heart rate over time. The primary outcome (p for trend = 0.0004) and its components CVD (p trend = 0.0002), first HHF (p for trend = 0.0099) and all-cause death (p < 0.0001) increased with RHR only in sinus rhythm but not AF. The risk increase with RHR was similar in patients with heart failure and mildly reduced ejection fraction (left ventricular ejection fraction [LVEF] 40-49%) and HFpEF (LVEF ≥50%). Baseline RHR had no influence on the effect of empagliflozin on the primary outcomes (p for trend = 0.20), first HHF (p for trend = 0.49). There were no clinically relevant differences in adverse events between empagliflozin and placebo across the RHR groups. CONCLUSION: Resting heart rate associates with outcomes only in sinus rhythm but not in AF. Empagliflozin reduced outcomes over the entire RHR spectrum without increase of adverse events.
Subject(s)
Atrial Fibrillation , Heart Failure , Humans , Stroke Volume , Heart Rate , Ventricular Function, Left , Atrial Fibrillation/complications , Atrial Fibrillation/drug therapyABSTRACT
Initiating insulin therapy with a basal insulin analogue has become a standard of care in the treatment of type 2 diabetes mellitus (T2DM). Despite increasing choices in pharmacological approaches, intensified glucose monitoring and improvements in quality of care, many patients do not achieve the desired level of glycaemic control. Although insulin therapy, when optimized, can help patients reach their glycaemic goals, there are barriers to treatment initiation on both the side of the patient and provider. Providers experience barriers based on their perceptions of patients' capabilities and concerns. They may lack the confidence to solve the practical problems of insulin therapy and avoid decisions they perceive as risky for their patients. In this study, we review recommendations for basal insulin initiation, focussing on glycaemic targets, titration, monitoring, and combination therapy with non-insulin anti-hyperglycaemic medications. We provide practical advice on how to address some of the key problems encountered in everyday clinical practice and give recommendations where there are gaps in knowledge or guidelines. We also discuss common challenges faced by people with T2DM, such as weight gain and hypoglycaemia, and how providers can address and overcome them.
Subject(s)
Diabetes Mellitus, Type 2 , Blood Glucose , Blood Glucose Self-Monitoring , Diabetes Mellitus, Type 2/drug therapy , Glycated Hemoglobin/analysis , Humans , Hypoglycemic Agents/therapeutic use , Insulin , Insulin, Regular, HumanABSTRACT
BACKGROUND: To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis and an inadequate response to methotrexate (MTX). METHODS: In this double-blind phase 3 study, patients were randomised 3:3:2 to placebo (n=488), baricitinib 4 mg once daily (n=487), or adalimumab 40 mg biweekly (n=330) with background MTX. PROs included the SF-36, EuroQol 5-D (EQ-5D) index scores and visual analogue scale, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain and Work Productivity and Activity Impairment Questionnaire-Rheumatoid Arthritis (WPAI-RA), and measures collected in electronic patient daily diaries: duration and severity of morning joint stiffness (MJS), Worst Ttiredness and Worst Joint Pain. The primary study endpoint was at week 12. Treatment comparisons were assessed with logistic regression for categorical measures or analysis of covariance for continuous variables. RESULTS: Compared with placebo and adalimumab, baricitinib showed statistically significant improvements (p≤0.05) in HAQ-DI, PtGA, pain, FACIT-F, SF-36 physical component score, EQ-5D index scores and WPAI-RA daily activity at week 12. Improvements were maintained for measures assessed to week 52. Statistically significant improvement in patient diary measures (MJS duration and severity), worst tiredness and worst joint pain were observed for baricitinib versus placebo and adalimumab at week 12 (p≤0.05). CONCLUSIONS: Baricitinib provided significantly greater improvement in most PROs compared with placebo and adalimumab, including physical function MJS, pain, fatigue and quality of life. Improvement was maintained to the end of the study (week 52). TRIAL REGISTRATION: NCT01710358.
Subject(s)
Adalimumab/therapeutic use , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Azetidines/therapeutic use , Patient Reported Outcome Measures , Sulfonamides/therapeutic use , Adult , Analysis of Variance , Arthralgia/etiology , Arthritis, Rheumatoid/complications , Double-Blind Method , Fatigue/etiology , Female , Humans , Logistic Models , Male , Middle Aged , Pain Measurement , Purines , Pyrazoles , Quality of Life , Severity of Illness Index , Surveys and Questionnaires , Treatment OutcomeABSTRACT
BACKGROUND: The 2-year prospective MOSAIc (Multinational Observational Study assessing Insulin use: understanding the challenges associated with progression of therapy) study is investigating whether patient-, physician-, and health system-related factors affect outcomes in patients with type 2 diabetes (T2D). This baseline subanalysis investigated how aspects of the patient-physician relationship are associated with diabetes-related distress, insulin adherence, and glycemic control. METHODS: Patients with T2D taking insulin for ≥3 months were recruited at primary care and specialty practice sites in 18 countries. Physicians provided usual care. Clinical history and most recent HbA1c values were collected; patients were surveyed regarding their perception of physician interactions, diabetes-related distress level, and insulin adherence. RESULTS: The analysis population comprised 4341 patients. Four (of six) domains showed a significant relationship with total diabetes-related distress (P < 0.01). Poor insulin adherence was associated with greater diabetes-related distress (adjusted odds ratio [aOR] 1.14; 95% confidence interval [CI] 1.06-1.22), higher Discrimination (aOR 1.13; 95% CI 1.02-1.27) and Hurried Communication (aOR 1.35; 95% CI 1.20-1.53) scores, and a lower Explained Results score (aOR 0.86; 95% CI 0.77-0.97). Poor insulin adherence was associated with a 0.43% increase in HbA1c, whereas a 1-unit increase in total diabetes-related distress and Hurried Communication scores was associated with a 0.171% and 0.145% increase in HbA1c, respectively. CONCLUSIONS: Patients distressed about living with T2D, and dissatisfied with aspects of their interactions with physicians, exhibited poor insulin adherence. Perceived physician inattention and lack of engagement (and diabetes-related distress) directly affect insulin adherence and glycemic control.
Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Insulin/therapeutic use , Medication Adherence , Physician-Patient Relations , Aged , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/psychology , Female , Glycated Hemoglobin/metabolism , Humans , Hypoglycemic Agents/therapeutic use , Linear Models , Logistic Models , Male , Middle Aged , Prospective Studies , Surveys and QuestionnairesABSTRACT
BACKGROUND: This post hoc analysis examined the efficacy and safety of twice-daily insulin lispro low mixture (LM25) and once-daily basal insulin glargine plus once-daily prandial insulin lispro (IGL) in a Latin American subpopulation with type 2 diabetes mellitus (T2DM). METHODS: A phase 4, randomized, open-label, parallel-arm trial included participants aged 18-75 years with T2DM taking once-daily insulin glargine and stable doses of metformin and/or pioglitazone with glycated hemoglobin (HbA1c) 7.5-10.5 % and fasting plasma glucose ≤121 mg/dL. Participants were randomized 1:1 to receive their stable dose of metformin and/or pioglitazone plus twice-daily LM25 or IGL for 24 weeks. The primary efficacy outcome was change in HbA1c after 24 weeks of treatment. Results from participants in Argentina, Brazil, and Mexico are presented here. RESULTS: 162 participants (80 LM25; 82 IGL) with mean ± standard deviation (SD) age = 57.3 ± 9.0 years and body mass index = 31.3 ± 5.2 kg/m(2) were included. Mean ± SD change in HbA1c from baseline to week 24 was -1.5 ± 1.0 % (LM25) and -1.1 ± 1.2 % (IGL). At week 24, 35.1 % (LM25) and 31.6 % (IGL) of participants achieved HbA1c <7.0 %. Mean ± SD weight gain from baseline to week 24 was 2.4 ± 2.9 kg in the LM25 group and 1.0 ± 3.1 kg in the IGL group. The mean ± SD rates of total hypoglycemia per year were 18.9 ± 27.3 (LM25) and 21.6 ± 31.1 (IGL). Rates of treatment-emergent adverse events were 46 % (LM25) and 39 % (IGL). CONCLUSIONS: Our results suggest that both LM25 and IGL are viable treatment options for insulin intensification in Latin American patients with T2DM with suboptimal glycemic control on basal insulin glargine. The safety and tolerability profiles of LM25 and IGL are consistent between this Latin American population and the global trial-level population. Trial registration NCT01175824.
ABSTRACT
OBJECTIVE: The aim of this post hoc analysis was to assess the efficacy and safety of once-weekly dulaglutide in Hispanic/Latino patients with type 2 diabetes (T2D) in phase 3 AWARD trials 1 to 6. METHODS: Hispanic/Latino data at Week 26 were pooled across studies for each dulaglutide dose to analyze the change from baseline in glycosylated hemoglobin (HbA1c), percent to HbA1c goal, and adverse events (AEs). Change from baseline in HbA1c, change from baseline in weight and hypoglycemia were analyzed by Hispanic/Latino and non-Hispanic/Latino subgroups for each study. RESULTS: Of the 3,136 patients randomized to dulaglutide 1.5 or 0.75 mg, 949 were reported as having Hispanic/Latino ethnicity. Baseline characteristics were similar for Hispanic/Latino and overall populations, except there were slightly more Hispanic/Latino females and weight was slightly lower for Hispanic/Latino patients. Hispanic/Latino patients receiving dulaglutide 1.5 mg had a reduction in HbA1c of 1.25% (95% confidence interval [CI]: -1.35, -1.15); dulaglutide 0.75 mg had a reduction of 1.07% (95% CI: -1.18, -0.96). Reductions in HbA1c and percent to goal HbA1c <7% and ≤6.5% were similar between Hispanic/Latino patients and the overall population. Weight change and hypoglycemia were similar between Hispanic/Latino and non-Hispanic/Latino subgroups for all studies. Treatment-emergent AEs were consistent with the overall population. CONCLUSION: Dulaglutide improved glycemic control with the potential for weight loss in Hispanic/Latino patients with T2D. Dulaglutide was well tolerated and had a low risk of hypoglycemia when used without insulin secretagogues or insulin. In the Hispanic/Latino population, dulaglutide efficacy and safety was consistent with that of the overall population. ABBREVIATIONS: AE = adverse event AWARD = Assessment of Weekly AdministRation of dulaglutide in Diabetes BID = twice daily CARMELA = The Cardiovascular Risk Factor Multiple Evaluation of Latin America CI = confidence interval GLP-1 RA = glucagon-like peptide-1 receptor agonist HbA1c = glycosylated hemoglobin T2D = type 2 diabetes.
Subject(s)
Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Glucagon-Like Peptides/analogs & derivatives , Hispanic or Latino/statistics & numerical data , Hypoglycemic Agents/pharmacology , Immunoglobulin Fc Fragments/pharmacology , Recombinant Fusion Proteins/pharmacology , Weight Loss/drug effects , Adult , Aged , Diabetes Mellitus, Type 2/ethnology , Female , Glucagon-Like Peptides/administration & dosage , Glucagon-Like Peptides/adverse effects , Glucagon-Like Peptides/pharmacology , Humans , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/adverse effects , Immunoglobulin Fc Fragments/administration & dosage , Immunoglobulin Fc Fragments/adverse effects , Male , Middle Aged , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/adverse effectsABSTRACT
BACKGROUND: Poor glycemic control in patients with type 2 diabetes is commonly recorded worldwide; Latin America (LA) is not an exception. Barriers to intensifying insulin therapy and which barriers are most likely to negatively impact outcomes are not completely known. The objective was to identify barriers to insulin progression in individuals with type 2 diabetes mellitus (T2DM) in LA countries (Mexico, Brazil, and Argentina). METHODS: MOSAIc is a multinational, non-interventional, prospective, observational study aiming to identify the patient-, physician-, and healthcare-based factors affecting insulin intensification. Eligible patients were ≥18 years, had T2DM, and were treated with insulin for ≥3 months with/without oral antidiabetic drugs (OADs). Demographic, clinical, and psychosocial data were collected at baseline and regular intervals during the 24-month follow-up period. This paper however, focuses on baseline data analysis. The association between glycated hemoglobin (HbA1c) and selected covariates was assessed. RESULTS: A trend toward a higher level of HbA1c was observed in the LA versus non-LA population (8.40 ± 2.79 versus 8.18 ± 2.28; p ≤ 0.069). Significant differences were observed in clinical parameters, treatment patterns, and patient-reported outcomes in LA compared with the rest of the cohorts and between Mexico, Brazil, and Argentina. Higher number of insulin injections and lower number of OADs were used, whereas a lower level of knowledge and a higher level of diabetes-related distress were reported in LA. Covariates associated with HbA1c levels included age (-0.0129; p < 0.0001), number of OADs (0.0835; p = 0.0264), higher education level (-0.2261; p = 0.0101), healthy diet (-0.0555; p = 0.0083), self-monitoring blood glucose (-0.0512; p = 0.0033), hurried communication style in the process of care (0.1295; p = 0.0208), number of insulin injections (0.1616; p = 0.0088), adherence (-0.1939; p ≤ 0.0104), and not filling insulin prescription due to associated cost (0.2651; p = 0.0198). CONCLUSION: MOSAIc baseline data showed that insulin intensification in LA is not optimal and identified several conditions that significantly affect attaining appropriate HbA1c values. Tailored public health strategies, including education, should be developed to overcome such barriers. Trial Registration NCT01400971.
ABSTRACT
Introducción. En 2007 y 2012, se implementaron en nuestro país las Encuestas Mundiales de Salud en Jóvenes (EMSE) y de Tabaco en Jóvenes (EMTJ) para estimar la prevalencia de comportamientos de riesgo y factores de protección entre los adolescentes de 13 a 15 años. Objetivo. Evaluar los cambios de los indicadores de alimentación y peso corporal, tabaco y actividad física en los últimos 5 años. Metodología. Estudio de corte transversal. Se utilizó un muestreo aleatorizado bietápico con selección de 600 escuelas a nivel nacional. Los estudiantes de las divisiones elegidas al azar fueron invitados a responder el cuestionario autoadministrado (de la EMSE o de la EMTJ). Resultados. En 2012, la encuesta fue respondida por 20 697 alumnos de 544 escuelas para la EMSE y 2062 para la EMTJ en 73 escuelas. Entre 2007 y 2012, se incrementó en forma significativa la prevalencia de sobrepeso (24,5% en 2007, 28,6% en 2012) y obesidad (4,4% en 2007, 5,9% en 2012), y se mantuvieron elevados los consumos de bebidas azucaradas y comidas rápidas. Se observó una leve mejora en el nivel de actividad física (12,7% en 2007, 16,7% en 2012) aunque continúa por debajo de lo recomendado. Se redujo la prevalencia de tabaquismo (24,5% en 2007, 19,6% en 2012), pero persiste elevado el acceso a productos del tabaco y la exposición al humo de tabaco ajeno en lugares públicos, incluso la escuela. Conclusiones. La progresión de la epidemia de sobrepeso y obesidad indica una necesidad de profundizar acciones en alimentación saludable y actividad física. A pesar del descenso de la prevalencia de tabaquismo, es necesario seguir fortaleciendo las acciones de control de tabaco.
Introduction. In2007and 2012, the Global School-Based Student Health Survey (GSHS) and the Global Youth Tobacco Survey (GYTS) were implemented to estimate the prevalence of risk behaviors and protection factors among 13 to 15 year-old adolescents. Objective. To assess changes in dietary, body weight, tobacco and physical activity indicators in the past five years. Population and Methos. Cross-sectional study. A randomized, two-stage sampling with 600 schools selected at a national level was used. Students from randomly selected courses were invited to answer a self-administered questionnaire (either the GSHS or the GYTS). Results. In 2012, the GSHS was completed by 20 697 students from 544 schools, while the GYTS was completed by 2062 students from 73 schools. Between 2007 and 2012, overweight and obesity prevalence significantly increased (overweight: 24.5% in2007, 28.6% in2012; obesity 4.4% in2007, 5.9% in 2012), while the consumption of sugar-sweetened beverages and fast food remained high. A slight improvement was observed in the level of physical activity (12.7% in 2007, 16.7% in 2012), although it remains below what is recommended. The prevalence of tobacco use was reduced (24.5% in 2007, 19.6% in 2012), but access to tobacco products and exposure to secondhand smoke remains high in public places, including schools. Conclusions. The spread of the overweight and obesity epidemic calls for a need to consolidate actions tending towards a healthy diet and physical activity. Despite a decrease in the prevalence of tobacco use, it is necessary to continue strengthening tobacco control actions.
Subject(s)
Humans , Adolescent , Public Policy , Prevalence , Risk Factors , Health Surveys , Adolescent Behavior , Noncommunicable DiseasesABSTRACT
Introducción. En 2007 y 2012, se implementaron en nuestro país las Encuestas Mundiales de Salud en Jóvenes (EMSE) y de Tabaco en Jóvenes (EMTJ) para estimar la prevalencia de comportamientos de riesgo y factores de protección entre los adolescentes de 13 a 15 años. Objetivo. Evaluar los cambios de los indicadores de alimentación y peso corporal, tabaco y actividad física en los últimos 5 años. Metodología. Estudio de corte transversal. Se utilizó un muestreo aleatorizado bietápico con selección de 600 escuelas a nivel nacional. Los estudiantes de las divisiones elegidas al azar fueron invitados a responder el cuestionario autoadministrado (de la EMSE o de la EMTJ). Resultados. En 2012, la encuesta fue respondida por 20 697 alumnos de 544 escuelas para la EMSE y 2062 para la EMTJ en 73 escuelas. Entre 2007 y 2012, se incrementó en forma significativa la prevalencia de sobrepeso (24,5% en 2007, 28,6% en 2012) y obesidad (4,4% en 2007, 5,9% en 2012), y se mantuvieron elevados los consumos de bebidas azucaradas y comidas rápidas. Se observó una leve mejora en el nivel de actividad física (12,7% en 2007, 16,7% en 2012) aunque continúa por debajo de lo recomendado. Se redujo la prevalencia de tabaquismo (24,5% en 2007, 19,6% en 2012), pero persiste elevado el acceso a productos del tabaco y la exposición al humo de tabaco ajeno en lugares públicos, incluso la escuela. Conclusiones. La progresión de la epidemia de sobrepeso y obesidad indica una necesidad de profundizar acciones en alimentación saludable y actividad física. A pesar del descenso de la prevalencia de tabaquismo, es necesario seguir fortaleciendo las acciones de control de tabaco.(AU)
Introduction. In2007and 2012, the Global School-Based Student Health Survey (GSHS) and the Global Youth Tobacco Survey (GYTS) were implemented to estimate the prevalence of risk behaviors and protection factors among 13 to 15 year-old adolescents. Objective. To assess changes in dietary, body weight, tobacco and physical activity indicators in the past five years. Population and Methos. Cross-sectional study. A randomized, two-stage sampling with 600 schools selected at a national level was used. Students from randomly selected courses were invited to answer a self-administered questionnaire (either the GSHS or the GYTS). Results. In 2012, the GSHS was completed by 20 697 students from 544 schools, while the GYTS was completed by 2062 students from 73 schools. Between 2007 and 2012, overweight and obesity prevalence significantly increased (overweight: 24.5% in2007, 28.6% in2012; obesity 4.4% in2007, 5.9% in 2012), while the consumption of sugar-sweetened beverages and fast food remained high. A slight improvement was observed in the level of physical activity (12.7% in 2007, 16.7% in 2012), although it remains below what is recommended. The prevalence of tobacco use was reduced (24.5% in 2007, 19.6% in 2012), but access to tobacco products and exposure to secondhand smoke remains high in public places, including schools. Conclusions. The spread of the overweight and obesity epidemic calls for a need to consolidate actions tending towards a healthy diet and physical activity. Despite a decrease in the prevalence of tobacco use, it is necessary to continue strengthening tobacco control actions.(AU)
ABSTRACT
INTRODUCTION: In 2007 and 2012, the Global School-Based Student Health Survey (GSHS) and the Global Youth Tobacco Survey (GYTS) were implemented to estimate the prevalence of risk behaviors and protection factors among 13 to 15 year-old adolescents. OBJECTIVE: To assess changes in dietary, body weight, tobacco and physical activity indicators in the past five years. POPULATION AND METHODS: Cross-sectional study. A randomized, two-stage sampling with 600 schools selected at a national level was used. Students from randomly selected courses were invited to answer a self-administered questionnaire (either the GSHS or the GYTS). RESULTS: In 2012, the GSHS was completed by 20 697 students from 544 schools, while the GYTS was completed by 2062 students from 73 schools. Between 2007 and 2012, overweight and obesity prevalence significantly increased (overweight: 24.5% in 2007, 28.6% in 2012; obesity 4.4% in 2007, 5.9% in 2012), while the consumption of sugar-sweetened beverages and fast food remained high. A slight improvement was observed in the level of physical activity (12.7% in 2007, 16.7% in 2012), although it remains below what is recommended. The prevalence of tobacco use was reduced (24.5% in 2007, 19.6% in 2012), but access to tobacco products and exposure to secondhand smoke remains high in public places, including schools. CONCLUSIONS: The spread of the overweight and obesity epidemic calls for a need to consolidate actions tending towards a healthy diet and physical activity. Despite a decrease in the prevalence of tobacco use, it is necessary to continue strengthening tobacco control actions.
Subject(s)
Motor Activity , Obesity/epidemiology , Overweight/epidemiology , Tobacco Use/epidemiology , Adolescent , Argentina/epidemiology , Cross-Sectional Studies , Diet Surveys , Female , Health Surveys , Humans , Male , Prevalence , Random Allocation , Schools , Time FactorsABSTRACT
INTRODUCTION: In 2007 and 2012, the Global School-Based Student Health Survey (GSHS) and the Global Youth Tobacco Survey (GYTS) were implemented to estimate the prevalence of risk behaviors and protection factors among 13 to 15 year-old adolescents. OBJECTIVE: To assess changes in dietary, body weight, tobacco and physical activity indicators in the past five years. POPULATION AND METHODS: Cross-sectional study. A randomized, two-stage sampling with 600 schools selected at a national level was used. Students from randomly selected courses were invited to answer a self-administered questionnaire (either the GSHS or the GYTS). RESULTS: In 2012, the GSHS was completed by 20 697 students from 544 schools, while the GYTS was completed by 2062 students from 73 schools. Between 2007 and 2012, overweight and obesity prevalence significantly increased (overweight: 24.5
in 2007, 28.6
in 2012; obesity 4.4
in 2007, 5.9
in 2012), while the consumption of sugar-sweetened beverages and fast food remained high. A slight improvement was observed in the level of physical activity (12.7
in 2007, 16.7
in 2012), although it remains below what is recommended. The prevalence of tobacco use was reduced (24.5
in 2007, 19.6
in 2012), but access to tobacco products and exposure to secondhand smoke remains high in public places, including schools. CONCLUSIONS: The spread of the overweight and obesity epidemic calls for a need to consolidate actions tending towards a healthy diet and physical activity. Despite a decrease in the prevalence of tobacco use, it is necessary to continue strengthening tobacco control actions.
ABSTRACT
INTRODUCCIÓN: La Encuesta Mundial de Tabaquismo en Adultos (EMTA) es el estándar para monitorear de forma sistemática el consumo y los principales indicadores de control del tabaco. OBJETIVO: Monitorear la epidemia de tabaquismo en adultos en Argentina con una herramienta estandarizada propuesta por la Organización Mundial de la Salud. MÉTODOS: Se utilizó la metodología estandarizada a nivel mundial para relevar la información sobre uso de tabaco (para fumar y sin humo), cesación del consumo, exposición al humo de tabaco ajeno (HTA), economía, medios de comunicación y conocimientos, actitudes y percepciones acerca del uso. Se utilizó un diseño muestral multietápico, estratificado por conglomerados, para generar datos representativos a nivel nacional y regional. RESULTADOS: Se evidenció una prevalencia de tabaquismo del 22,3%, mayor en varones (29,6%) que en mujeres (15,7%). El 73,6% de los fumadores había planeado o estaba pensando en dejar de fumar, y el 48,6% había hecho un intento el último año. El 31,6% de los adultos que trabajaban en ambientes cerrados había estado expuesto allí a HTA; el 33% sufrió esa exposición en su hogar. El 75,8% obtuvo información sobre los peligros de fumar en medios de comunicación, mientras que el 41,9% advirtió publicidades de cigarrillos en los sitios de venta. CONCLUSIONES: La encuesta permitió conocer con mayor profundidad las características de la epidemia de tabaquismo en Argentina y realizar una comparación a nivel mundial.
INTRODUCTION: The Global Adult Tobacco Survey (GATS) is the world standard to sy stematically monitor tobacco consumption and the main indicators for tobacco control. OBJECTIVE: To monitor tobacco epidemic in adults in Argentina with a standardized tool suggested by the World Health Organization. METHODS: A globally standardized methodology was used to gather information on tobacco use (smoking and smokeless), cessation, second-hand smoke (SHS), economics, media, and knowledge, attitudes and perceptions towards tobacco use. A multi-stage stratified cluster sample design was used to produce representative data both at national and regional level. RESULTS: Tobacco smoking prevalence was 22.3%, with a high errate in men (29.6%) than in women (15.7%). A total of 73.6% of the smokers had planned or was planning to quit, and 48.6% had made a quit attempt in the previous year. Among adults working in enclosed places 31.6% were exposed to SHS, and 33% were exposed at home. Besides, 75.8% obtained anti-cigarette smoking information on mass media, while 41.9% noticed advertising at cigarette stores. CONCLUSIONS: The survey allowed a better understanding of tobacco epidemic in Argentina and also a comparison with other countries in the worl.
Subject(s)
Humans , Statistical Data , Health Workforce , Health Policy, Planning and Management , Smoking/epidemiology , Smoking/prevention & controlABSTRACT
OBJECTIVE: To identify main barriers to preventing cardiovascular disease and implementing clinical practice guidelines in primary care, to pilot implementation of a tailored enactment of the adapted World Health Organization guidelines to prevent cardiovascular disease, and to assess the impact of the intervention in risk stratification. METHODS: A qualitative study was done with decision makers, health professionals, and staff from five primary health care centers, who were interviewed to identify the main barriers. A tailored intervention to apply the guidelines was then designed and implemented. To assess the impact of the intervention on risk factor screening, a before-and-after analysis was performed through a records review of independent samples of patients aged 40 years or older attending each center. RESULTS: The main barriers identified were lack of awareness of guidelines and lack of knowledge about preventing cardiovascular disease, communication problems within health teams, lack of motivation, and organizational problems. Before (n = 226) and after (n = 234) the intervention, screening of the main risk factors increased: blood pressure measurement from 44.3% to 72.6%, cholesterol measurement from 20.7% to 49.7%, smoking status assessment from 20.4% to 56.1%, diabetes status assessment from 25.5% to 93.6%, and previous vascular event status from 33.2% to 74.3%. Global risk stratification was not done at baseline, compared with 45.1% after the intervention. CONCLUSIONS: The main barriers identified were useful in designing a tailored intervention. Although no clinical outcomes were evaluated, this study shows that the implementation is feasible, with increased risk stratification as a first step at better patient management.
Subject(s)
Cardiovascular Diseases/prevention & control , Primary Health Care , Argentina , Female , Humans , Male , Middle Aged , Primary Prevention/organization & administration , Risk AssessmentABSTRACT
OBJECTIVE: To identify main barriers to preventing cardiovascular disease and implementing clinical practice guidelines in primary care, to pilot implementation of a tailored enactment of the adapted World Health Organization guidelines to prevent cardiovascular disease, and to assess the impact of the intervention in risk stratification. METHODS: A qualitative study was done with decision makers, health professionals, and staff from five primary health care centers, who were interviewed to identify the main barriers. A tailored intervention to apply the guidelines was then designed and implemented. To assess the impact of the intervention on risk factor screening, a before-and-after analysis was performed through a records review of independent samples of patients aged 40 years or older attending each center. RESULTS: The main barriers identified were lack of awareness of guidelines and lack of knowledge about preventing cardiovascular disease, communication problems within health teams, lack of motivation, and organizational problems. Before (n = 226) and after (n = 234) the intervention, screening of the main risk factors increased: blood pressure measurement from 44.3% to 72.6%, cholesterol measurement from 20.7% to 49.7%, smoking status assessment from 20.4% to 56.1%, diabetes status assessment from 25.5% to 93.6%, and previous vascular event status from 33.2% to 74.3%. Global risk stratification was not done at baseline, compared with 45.1% after the intervention. CONCLUSIONS: The main barriers identified were useful in designing a tailored intervention. Although no clinical outcomes were evaluated, this study shows that the implementation is feasible, with increased risk stratification as a first step at better patient management.
OBJETIVO: Determinar las principales barreras en la prevención de las enfermedades cardiovasculares y la aplicación de las directrices de práctica clínica en atención primaria, guiar la adecuada puesta en práctica de las directrices adaptadas de la Organización Mundial de la Salud para prevenir las enfermedades cardiovasculares, y evaluar la repercusión de la intervención en la estratificación del riesgo. MÉTODOS: Se llevó a cabo un estudio cualitativo dirigido a los encargados de adoptar las decisiones, los profesionales de la salud y el personal de cinco centros de atención primaria de salud, que fueron entrevistados con objeto de determinar las principales barreras. Posteriormente se diseñó y ejecutó una intervención adaptada para aplicar las directrices. Con objeto de evaluar la repercusión de la intervención sobre el tamizaje de los factores de riesgo, se llevaron a cabo un análisis anterior y posterior a la intervención mediante un examen de los registros de muestras independientes de pacientes de 40 años o mayores que acudían a cada centro. RESULTADOS: Las principales barreras detectadas fueron el desconocimiento de las directrices y la carencia de información sobre la prevención de las enfermedades cardiovasculares, los problemas de comunicación dentro de los equipos de salud, la falta de motivación y los problemas organizativos. Al comparar los datos previos a la intervención (n = 226) con los posteriores a esta (n = 234), se observó un incremento del tamizaje de los principales factores de riesgo: la medición de la presión arterial de 44,3 a 72,6%, la determinación del colesterol de 20,7 a 49,7%, la evaluación de la presencia de tabaquismo de 20,4 a 56,1%, la evaluación de la presencia de diabetes de 25,5 a 93,6% y la evaluación de la presencia de un episodio vascular anterior de 33,2 a 74,3%. Al inicio del estudio no se llevaba a cabo la estratificación del riesgo global, en comparación con el 45,1% de estratificación realizada posteriormente a la intervención. CONCLUSIONES: La determinación de las principales barreras fue útil para el diseño de una intervención adaptada. Aunque no se evaluaron los resultados clínicos, este estudio revela que la ejecución es factible, y que la mayor estratificación del riesgo constituye un primer paso en la mejora de la atención de los pacientes.
Subject(s)
Humans , Male , Female , Middle Aged , Cardiovascular Diseases/prevention & control , Primary Health Care , Argentina , Primary Prevention/organization & administration , Risk AssessmentABSTRACT
OBJECTIVES: To evaluate how socio-economic gradients in NCDs and NCD-related risk factors change over time. METHODS: Secondary analysis of cross-sectional data from the 2005 and 2009 Argentine National Risk Factor Surveys (N = 41,392 and N = 34,732) was conducted. We analyzed inequalities in three risk factors (low physical activity, obesity, and diabetes) according to income and educational attainment. The analysis was based on sex-stratified and age-adjusted logistic regression. RESULTS: The overall prevalence of low physical activity, obesity, and diabetes increased from 2005 to 2009. Increases occurred in most of the income and education groups, but females with the lowest socio-economic status generally showed the highest increases. In 2005, differences in physical inactivity among women with different levels of education were not statistically significant. By 2009, women with low education (OR = 1.57, 95 % CI = 1.34-1.84) and medium education (OR = 1.18, 95 % CI = 1.06-1.32) were more likely than women with high education to be physically inactive. CONCLUSION: Inequalities in physical inactivity, obesity, and diabetes have grown in Argentina over a short period of time.
Subject(s)
Diabetes Mellitus/epidemiology , Exercise/physiology , Obesity/epidemiology , Sedentary Behavior , Social Class , Adult , Argentina/epidemiology , Cross-Sectional Studies , Female , Humans , Logistic Models , Male , Middle Aged , Prevalence , Risk Factors , Sex DistributionABSTRACT
BACKGROUND: Chagas disease affects mainly poor populations in Latin America. This review assesses the evidence on the independent risk of cardiovascular events associated with positive Chagas serology. METHODS: We searched for studies using the following outcomes: death, stroke, new onset heart failure, heart failure hospitalization or evidence of left ventricular dysfunction. Studies comparing patients with positive serology for Chagas with a control group with a follow-up longer than 1 year were selected. The Medline, Lilacs and Embase databases were searched on 21 January 2011 without restrictions. RESULTS: From 5236 potentially relevant studies, 25 fulfilled the inclusion criteria. Fourteen included patients with heart failure, six with severe symptoms and nine with mild symptoms or asymptomatic patients with low ejection fraction. In four studies of patients in functional class III or IV and in three studies of patients with mild symptoms, a higher risk of death was reported among those with positive serology for Chagas. Of the 11 studies of patients without symptoms or low ejection fraction, 3 showed a higher risk of mortality related to Chagas exposure. Two of these were based on the same cohort of people aged >60 years. Overall, 8 out of the 14 heart failure studies and 2 out of the 11 heart damage studies adjusted for confounding factors. CONCLUSION: Positive serology for Chagas is associated with a higher risk of death for patients with heart failure. However, there is little evidence to link positive serology for Chagas with cardiovascular events in asymptomatic subjects.
Subject(s)
Chagas Cardiomyopathy/epidemiology , Age Factors , Chagas Cardiomyopathy/mortality , Heart Failure/epidemiology , Hospitalization/statistics & numerical data , Humans , Latin America/epidemiology , Socioeconomic Factors , Stroke/epidemiology , United States/epidemiology , Ventricular Dysfunction, Left/epidemiologyABSTRACT
BACKGROUND: The Food Frequency Questionnaire (FFQ) is the most commonly used method for ranking individuals based on long term food intake in large epidemiological studies. The validation of an FFQ for specific populations is essential as food consumption is culture dependent. The aim of this study was to develop a Semi-quantitative Food Frequency Questionnaire (SFFQ) and evaluate its validity and reproducibility in estimating nutrient intake in urban and rural areas of Argentina. METHODS/PRINCIPAL FINDINGS: Overall, 256 participants in the Argentinean arm of the ongoing Prospective Urban and Rural Epidemiological study (PURE) were enrolled for development and validation of the SFFQ. One hundred individuals participated in the SFFQ development. The other 156 individuals completed the SFFQs on two occasions, four 24-hour Dietary Recalls (24DRs) in urban, and three 24DRs in rural areas during a one-year period. Correlation coefficients (r) and de-attenuated correlation coefficients between 24DRs and SFFQ were calculated for macro and micro-nutrients. The level of agreement between the two methods was evaluated using classification into same and extreme quartiles and the Bland-Altman method. The reproducibility of the SFFQ was assessed by Pearson correlation coefficients and Intra-class Correlation Coefficients (ICC). The SFFQ consists of 96 food items. In both urban and rural settings de-attenuated correlations exceeded 0.4 for most of the nutrients. The classification into the same and adjacent quartiles was more than 70% for urban and 60% for rural settings. The Pearson correlation between two SFFQs varied from 0.30-0.56 and 0.32-0.60 in urban and rural settings, respectively. CONCLUSION: Our results showed that this SFFQ had moderate relative validity and reproducibility for macro and micronutrients in relation to the comparison method and can be used to rank individuals based on habitual nutrient intake.